Financial Ratios

WELCURE DRUGS & PHARMACEUTICALS LTD.

NSE : NABSE : 524661ISIN CODE : INE331C01017Industry : TradingHouse : Private
BSE4.40-0.02 (-0.45 %)
PREV CLOSE ( ) 4.42
OPEN PRICE ( ) 4.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10366
TODAY'S LOW / HIGH ( )4.40 4.40
52 WK LOW / HIGH ( ) 3.25.48
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)0.080.020.05-0.010.00
   CEPS(Rs)0.080.020.05-0.010.00
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)1.130.080.060.010.02
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)22.5241.26-11.642.91
   EBIT Margin(%)22.5241.42-11.274.99
   Pre Tax Margin(%)22.4641.36-11.394.88
   PAT Margin (%)22.4641.36-11.394.88
   Cash Profit Margin (%)22.4641.36-11.394.88
Performance Ratios
   ROA(%)12.5127.77112.99-34.5414.57
   ROE(%)12.6529.03131.74-49.4617.83
   ROCE(%)12.6729.12131.94-48.9418.22
   Asset Turnover(x)0.001.242.733.032.99
   Sales/Fixed Asset(x)0.00
   Working Capital/Sales(x)0.001.691.925.773.35
Efficiency Ratios
   Fixed Capital/Sales(x)0.000.000.000.00
   Receivable days0.000.000.000.00
   Inventory Days0.000.000.000.00
   Payable days
Valuation Parameters
   PER(x)53.10501.0341.320.00165.62
   PCE(x)51.48502.1341.31-51.57165.62
   Price/Book(x)3.57127.3132.8233.9027.09
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)112.1316.735.817.89
   EV/Core EBITDA(x)51.40497.8940.39-51.55158.27
   EV/EBIT(x)53.02497.8940.39-51.55158.27
   EV/CE(x)3.53121.6130.5519.4921.03
   M Cap / Sales112.7617.095.888.08
Growth Ratio
   Net Sales Growth(%)-100.00-21.2661.633.7759.00
   Core EBITDA Growth(%)344.39-57.19693.92-334.64120.54
   EBIT Growth(%)330.78-57.19693.92-334.64120.54
   PAT Growth(%)331.41-57.24686.68-342.39119.99
   EPS Growth(%)288.21-57.14683.33-343.74120.00
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.000.00
   Current Ratio(x)0.4317.3020.332.394.88
   Quick Ratio(x)0.4317.3020.332.394.88
   Interest Cover(x)703.02346.74636.34-93.0046.36
   Total Debt/Mcap(x)0.000.000.000.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.